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Abstract
Background: To study the effect of administration of tranexamic acid on the use of blood and
blood products, return to theatre for post-operative bleeding and the length of intensive care stay
after primary cardiac surgery, data for 4191 patients, of all priorities, who underwent primary
cardiac operation during the period between 30/10/00 and 21/09/04 were analysed.
Methods: Retrospective analysis of data collected prospectively during the study period. The main
outcome measures were whether or not patients were transfused with red blood cells, fresh
frozen plasma or any blood product, the proportion of patients returned to theatre for
investigation for post-operative bleeding and len g t h  o f  s t a y  i n  t h e  intensive care unit. We
performed univariate analysis to identify the factors influencing the outcome measures and
multivariate analysis to identify the effect of administration of tranexamic acid on the outcome
measures.
Results: Administration of tranexamic acid was an independent factor affecting the transfusion of
red blood cells, fresh frozen plasma or any blood product. It was also an independent factor
influencing the rate of return to theatre for exploration of bleeding. The odds of receiving a
transfusion or returning to theatre for bleeding were significantly lower in patients receiving
tranexamic acid. The administration of tranexamic acid also significantly decreased blood loss. We
did not find any association between the administration of tranexamic acid and the length of
intensive care stay.
Conclusion: Based on the analysis of 4191 patients who underwent a primary cardiac operation,
administration of tranexamic acid decreased the number of patients exposed to a transfusion or
returned to theatre for bleeding in our institute.
Background
Tranexamic acid is an antifibrinolytic agent used in the
control of bleeding under various circumstances [1] and
has been used to minimise bleeding after cardiac surgery
[2,3]. In cardiac surgery, postoperative bleeding is associ-
ated with an increased incidence of surgical re-exploration
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to identify the source of bleeding; increased use of blood;
significant morbidity such as renal failure, sepsis, arrhyth-
mias, prolonged requirement for mechanical ventilatory
support and longer hospital stay; and increased mortality
[4-8].
Randomised prospective studies have shown that tran-
examic acid can decrease exposure to blood transfusions
[9-14]. Unfortunately, those studies used a variety of dose
regimens and gave diverse conclusions, making it difficult
to translate these findings to the clinical arena with confi-
dence that it will indeed be a useful treatment. However,
our transfusion hospital guidelines have stated for the last
few years that we should administer tranexamic acid at a
dose of 2 g intravenously for any cardiac operation that
involves use of cardiopulmonary bypass and where apro-
tinin is not administered.
In an effort to control the cost of transfusion and to ensure
that all blood products are only used where appropriate,
our hospital employs a clinical information analyst who
is solely responsible for collecting prospectively, continu-
ously and at the bedside, all data related to transfusions in
connection with cardiac surgery. Compliance with guide-
lines is constantly assessed and reported and data
reviewed by this analyst showed that the institutional
antifibrinolytic guidelines were, in fact, not strictly
adhered to (Table 1).
We therefore decided to investigate the impact of tran-
examic acid administration on the use of red blood cells
and other blood products using the data collected pro-
spectively in our hospital from 30/10/00 to 21/09/04.
This reports comes at a time when the safety of aprotinin
is reviewed in light of recent evidence suggesting that
aprotinin may have a major negative impact on outcome
and that alternatives drugs, such as tranexamic acid, may
not only be cheaper but also safer alternatives [15,16].
Aprotinin is an antifibrinolytic agent whose efficacy on
decreasing perioperative transfusion has been extensively
and rigorously documented [17] and concerns on its
safety has indeed prompted numerous reactions [17-20].
Methods
To answer our specific question, we performed a retro-
spective analysis on prospectively collected data. The data
was collected between 30/10/00 and 21/09/04 in Pap-
worth Hospital, Cambridge, UK.
Data collection
Our hospital employs a full time clinical information ana-
lyst who is solely responsible for continuously collecting
all data relevant to blood loss and blood transfusions
from all patients undergoing cardiac surgery. The data col-
lection is prospective and occurs daily at the bedside as
part of the ongoing and continuous audit process in the
hospital. These data are audited regularly and information
fed back to all staff to ensure effective use of blood and
blood products. Initially these audits were conducted for
a specified number of weeks, but now the audit process is
continuous. Each audit now runs from 1st January to 31st
December, for the purposes of analysis.
Transfusion guidelines
Specific guidelines exist for the use of all blood products
throughout the hospital (Figure 1). These guidelines were
based on data collected from a previous audit, literature
review and institutional consensus. To support medical
decision, we routinely use a graph to represent the cumu-
lative post-operative blood loss over time in our patients
against a representation of the median blood loss of
untransfused patients not returned to theatre for excessive
bleeding (Figure 2). Adherence to the guidelines is moni-
tored daily by the clinical information analyst.
Antifibrinolytic administration
We have an institutional protocol for administration of
antifibrinolytic agents stating that tranexamic acid should
be given to all patients undergoing cardiopulmonary
bypass and not receiving aprotinin. Whenever tranexamic
acid is administered, it is given as an intravenous injection
of 2 g in total with 1 g before and 1 g after cardiopulmo-
nary bypass.
Inclusion and exclusion criteria
The data from all patients, of all priorities, who under-
went primary coronary artery bypass graft (CABG) sur-
gery, single valve surgery (either repair or replacement) or
combined CABG and single valve operations during the
Table 1: Variation in tranexamic acid administration between 
anaesthetists at this hospital, within the timeframe studied.
Number of patients (%)
Anaesthetist Total Tranexamic acid No Tranexamic acid
1 624 (14) 519 (83) 105 (17)
2 453 (11) 255 (56) 198 (44)
3 437 (10) 385 (88) 52 (12)
4 437 (10) 346 (79) 91 (21)
5 421 (10) 380 (90) 41 (10)
6 344 (8.2) 282 (82) 62 (18)
7 342 (8.2) 293 (86) 49 (14)
Other 1133 (27) 899 (79) 234 (21)
Variation in tranexamic acid administration, between anaesthetists at 
this hospital, for individual anaesthetists performing more than 300 
cases within the timeframe studied. Other anaesthetist includes all the 
anaesthetists who each performed less than 300 cases in the 
timeframe studied. The proportion of patients receiving tranexamic 
acid within this group varied from 56% to 90% depending upon 
anaesthetist.BMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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period 30/10/00 to 21/09/04 were included for the anal-
ysis. Patients who received aprotinin were excluded.
Outcomes of interest
Blood loss and blood transfusion are common occur-
rences after cardiac surgery and are associated with surgi-
cal re-exploration. Our aim was to identify whether
administration of tranexamic acid, in our clinical setting,
had an effect on blood transfusion and if its administra-
tion was an independent factor influencing whether a
patient would be taken back to theatre for re-exploration
or stay longer in the intensive care unit (ICU). We consid-
ered these outcomes as a binary measure and selected five
primary outcomes of interest:
a. Whether or not a patient received a transfusion of red
blood cells (RBC)
b. Whether or not a patient received a transfusion of fresh
frozen plasma (FFP)
c. Whether or not a patient received any transfusions
(including RBC, FFP, platelets and cryoprecipitate)
d. Whether or not a patient had to return for surgical re-
exploration
e. Whether or not a patient stayed in ICU for more than 1
day.
Another outcome measure was added on request of the
Journal Editor, asking whether the administration of tran-
examic acid decreased blood loss.
Analysis of the data
The analysis of the data was done in four steps:
(1) Initially, we compared the baseline characteristics of
the patients who received tranexamic acid (TA group) and
who did not receive tranexamic acid (NTA group). These
were age, sex, body mass index (BMI), priority of the sur-
gery (elective, urgent or emergency), type of surgery
(CABG, valve or combined), additive EuroSCORE. As the
data collection was part of the audit process, we also
assessed whether there was difference in the proportion of
Record of cumulative blood loss, used prospectively to  assess post-operative blood loss Figure 2
Record of cumulative blood loss, used prospectively to 
assess post-operative blood loss. Median and 95th centile val-
ues are based on post-operative blood loss from first time 
coronary artery bypass graft patients who did receive any 
blood products and who were not returned to theatre for 
bleeding.
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Guidelines for the administration of blood products at our  institution Figure 1
Guidelines for the administration of blood products at our 
institution.
If bleeding continues, send clotting and
full blood count to laboratory
Clotting screen results from lab
If results are normal, consider surgery
If rate of bleeding is > 3 ml.kg
-1.h
-1 for the
first 30 minutes, give 50 mg protamine
(APTT – activated partial thromboplastin time, PT – prothrombin time, FFP – fresh frozen
plasma, Hb – haemoglobin, RBC – red blood cells)
Give 1 pooled unit of platelets < 100 x 10
9.L 150 – 450 x 10
9.L Platelets
Give 5 units cryoprecipitate < 1.0 g.L 1.8 – 4.0 g.L Fibrinogen
Give 1 unit RBC < 8.5 g.dL Hb
> 21 seconds 10 – 14 seconds PT
Give FFP 12 mL.Kg > 48 seconds 25 – 35 seconds APTT
Treatment Trigger value Normal rangeBMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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patients receiving tranexamic acid over time, by compar-
ing the number of patients treated in each audit. Tests
used were Chi-square test (categorical variables), Mann-
Whitney U test and two-sample Student t-test (continuous
variables).
(2) In the second step, we used univariate logistic regres-
sion to assess the effect of administration of tranexamic
acid on each of the 5 main outcomes of interest. We also
used this method to identify other covariates that had an
effect on the outcome measures. The covariates consid-
ered were the baseline characteristics as listed above, as
well as time of audit, preoperative haemoglobin, bypass
time, preoperative aspirin use, preoperative clopidogrel
use, the anaesthetist involved and the surgeon. Preopera-
tive aspirin and clopidogrel use were analysed without
taking into consideration the time of administration of
the drug. Those patients recorded as having taken the
drug, irrespective of the time when they were stopped,
were considered as using the drug preoperatively. The cov-
ariates surgeon and anaesthetist were analysed using one
surgeon and one anaesthetist as a reference respectively
and assessing the effects of others by univariate analysis.
(3) In the third step, we built up a multiple logistic regres-
sion model (initially using forward selection and then ver-
ified by backward elimination) to adjust for the effects of
the baseline characteristics and the other covariates and to
assess whether the administration of tranexamic acid had
an independent effect on the outcome measures.
(4) In the fourth step, we performed two subgroup analy-
ses of the data.
(4.1) The first analysis considered only patients who
received a transfusion. Our analysis so far had looked at
transfusion as a binary outcome; that is, whether or not
patients received a transfusion. Here, we used a Mann-
Whitney U test to assess whether there was any difference
in the amount of red blood cells and other blood products
transfused in the two groups (TA and NTA).
(4.2) The second analysis considered only patients who
did not return to theatre for investigation of excessive
blood loss. Patients who returned to theatre belong to a
high-risk group for receiving transfusions and are likely to
stay longer in ICU. It was a concern, therefore, that these
patients may obscure trends in the data relating to tran-
examic acid. Hence, we excluded the patients who
returned to theatre for investigation of excessive blood
loss and repeated the same statistical tests on this new
group to identify the effects of administration of tran-
examic acid on the outcome measures of interest.
(5) In the final step we considered the blood loss out-
come. Total blood loss and 12 hour blood loss were com-
pared between the TA and NTA groups using the Mann-
Whitney U test. Separate comparisons were made for
those who were and were not returned to theatre for fur-
ther investigation. Multivariate linear regression was then
performed to assess which covariates had an independent
effect on total blood loss. The same set of covariates was
considered, and stepwise procedures were performed, as
before. Since the distribution of blood loss was positively
skewed, the outcome was transformed prior to modelling
using the natural log transformation. Results are therefore
reported as the proportionate change in blood loss attrib-
utable to a given covariate (i.e. the exponentiated coeffi-
cient corresponding to that covariate).
Statistical analyses were performed using SPSS (Statistical
Package for the Social Sciences) for Windows, version
12.0.
This work has not required ethical approval as it is based
on information collected as part of a routine audit pro-
gram, and Local Caldecott Guardian approval was
obtained for publication of these data.
Results
We identified data for 4191 patients who had undergone
primary coronary artery bypass grafting surgery (CABG),
single valve surgery (repair or replacement) or both proce-
dures combined between 30/10/00 and 21/09/04. Base-
line characteristics of patients are shown in Table 2.
Seventy five percent (n = 3153) of the patients were men
and 70 percent of all patients (n = 2933) were scheduled
for CABG. Forty seven percent of all patients (n = 1970)
received a transfusion and 5.5 percent of all patients (n =
229) returned to theatre for investigation of excessive
blood loss.
Eighty percent of all patients (n = 3359) received tran-
examic acid (TA group). There were no differences
between the groups with respect to sex, priority of surgery
and BMI. When compared to the overall baseline charac-
teristics, patients in the TA group were older, had a higher
EuroSCORE and had a higher proportion of combined
operations. The differences in age and EuroSCORE,
though statistically significant were not clinically signifi-
cant (Table 2). It was noted that the proportion of patients
receiving tranexamic acid has increased over the last four
years (Table 3). The difference in the proportion of
patients receiving tranexamic acid over time was found to
be statistically significant (p < 0.001, Chi-Square test).
A higher proportion of patients in the no tranexamic acid
(NTA) group received a transfusion and returned to thea-
tre for investigation of excessive blood loss. UnivariateBMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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logistic regression analysis showed that the odds of receiv-
ing a transfusion of red blood cells, fresh frozen plasma or
any blood product or returning to theatre for excessive
blood loss were lower in TA group (Table 4). However, we
did not find any difference in the proportion of patients
remaining in ICU beyond one day between the groups.
Univariate logistic regression was also used to identify if
other covariates had an effect on the outcome measures.
The results of this univariate analysis are given in Table 5.
All the covariates were found to affect at least one of the
outcome measures. Patients were more likely to receive a
transfusion if they were female, were older, had an emer-
gency operation, had a combined procedure, had a lower
BMI, had a higher EuroSCORE, had lower haemoglobin
preoperatively, used clopidogrel preoperatively or did not
use aspirin preoperatively when compared to the baseline
characteristics of the group. The surgeon and the anaes-
thetist also influenced on whether or not patients received
a transfusion and the overall effect was significant (Table
6, overall p value < 0.05).
This analysis also showed that the odds of being returned
to theatre were higher if the patients were male, were
older, had a lower BMI, had a higher EuroSCORE, had a
longer bypass time, had an emergency operation or had a
Table 3: Trend in the administration of tranexamic acid over time.
Number of patients (n = 4191)
Audit Time frame Total (%) TA group (%) NTA group (%)
1 30/10/00 – 18/02/01 348 (8) 247 (71) 101 (29)
2 23/04/01 – 02/09/01 413 (10) 277 (67) 136 (33)
3 12/11/01 – 20/12/02 1345 (32) 1139 (85) 206 (15)
4 20/01/03 – 31/12/03 1136 (27) 951 (84) 185 (16)
5 01/01/04 – 21/09/04 949(23) 745 (78) 204 (22)
Trend in the administration of tranexamic acid over time. Implementation of new antifibrinolytic guidelines resulted in an overall increase in the 
number of patients receiving tranexamic acid (p < 0.001, Chi-Square test, significant). (TA – tranexamic acid, NTA – no tranexamic acid)
Table 2: Baseline characteristics of the patient cohort analysed.
Variable  Whole Cohort  TA group  NTA group  p value
TA vs. NTA 
All patients (n, %) 4191 3359 (80) 832 (20) -
Sex (n, %)
Male 3153 (75) 2537 (76) 616 (74) 0.373
Priority (n, %)
Elective 3437 (82) 2750 (82) 687 (82) 0.839
Urgent 687 (16) 556 (16) 131 (16)
Emergency 67 (2) 53 (2) 14 (2)
Surgery type (n, %)
CABG 2933 (70) 2338 (70) 595 (72) 0.035
Valve 818 (20) 648 (19) 170 (20)
Combined 440 (10) 373 (11) 67 (8)
Mean Age (SD) 67 (10.2) 67.2 (10.2) 66.3 (10.3) 0.019
Mean BMI (SD) 27.5 (4.4) 27.5 (4.4) 27.7 (4.6) 0.215
EuroSCORE (Median, IQR) 4 (2,6) 4 (2,6) 4 (2,6) 0.014
Transfusion (n, %)
RBC 1933 (46) 1513 (45) 420 (50) 0.005
FFP 383 (9.1) 288 (8.6) 95 (11) 0.011
Any blood products 1970 (47) 1543 (46) 427 (51) 0.005
Return to theatre (n, %) 229 (5.5) 160 (4.8) 69 (8.3) < 0.001
ICU stay > 1 day (n, %) 933 (22) 735 (22) 198 (24) 0.234
Baseline characteristics of the patient cohort analysed. Patients who were in the tranexamic acid group were older, had a higher EuroSCORE (mean 
(SD) 4.61 (3.12) compared to4.36 (3.13) in the NTA group) and higher proportion of them underwent combined procedures. Despite this, the 
rates of transfusion of RBC, FFP, all blood products and the rate of return to theatre for bleeding were lower for patients in this group. (TA – 
tranexamic acid, NTA – no tranexamic acid, SD – Standard Deviation, CABG – coronary artery bypass grafting, Valve – single valve repair or 
replacement, combined – coronary artery bypass grafting and single valve surgery, BMI – body mass index, RBC – red blood cells, FFP – fresh frozen 
plasma, ICU – intensive care unit, n – number, IQR – inter quartile range)BMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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combined operation (Table 5). The surgeon, but not the
anaesthetist, also had an influence on the likelihood of a
patient returning to theatre (Table 6, overall p value for
surgeon < 0.05). However, preoperative haemoglobin and
use of aspirin or clopidogrel did not show any association
with the rates of return to theatre. Patients were more
likely to stay for greater than 1 day in the ICU if they were
older, were female, had a higher EuroSCORE, had lower
preoperative haemoglobin, used clopidogrel preopera-
tively, had an emergency operation or had a combined
operation when compared to the baseline characteristics.
BMI did not have an effect on the length of ICU stay when
assessed as a continuous variable.
After consideration of all of the above covariates, the final
multivariate model for predicting red blood cell transfu-
sion incorporated terms for audit time, age, BMI, Euro-
SCORE, sex, priority, surgery type, preoperative
haemoglobin, bypass time and surgeon. Aspirin use,
clopidogrel use and anaesthetist were found to be non-
significant after adjustment for other covariates. The mul-
tivariate model for predicting any blood product transfu-
sion incorporated the same terms as the red blood cell
model, as did the FFP model, with the exception of sex
and haemoglobin, which were found to be non-signifi-
cant after adjustment for other covariates. The model pre-
dicting returns to theatre incorporated all of the above
terms with the exception of haemoglobin. The ICU stay
model incorporated all of the above terms with the excep-
tion of age and sex, which were excluded, and with the
addition of anaesthetist, which was found to be signifi-
cant in predicting ICU stay. This analysis showed that,
after adjustment for these covariates, the administration
of tranexamic acid had an independent effect on adminis-
Table 5: Univariate analysis of the other covariates.Univariate analysis of the other covariates.
Odds Ratio (95% Confidence Interval) 
Covariates RBC transfusion FFP transfusion Any blood product transfusion Return to theatre ICU stay
Male Reference1 Reference1 Reference1 Reference1 Reference1
Female 4.95 (4.23, 5.79)* 1.29 (1.02, 1.62)* 4.83 (4.13, 5.65)* 0.77 (0.56, 1.08)* 1.38 (1.17, 1.62)*
Elective Reference1 Reference1 Reference1 Reference1 Reference1
Urgent 2.83 (2.38, 3.36)* 2.45 (1.93, 3.12)* 2.98 (2.50, 3.54)* 1.79 (1.31, 2.45)* 2.68 (2.25, 3.20)*
Emergency 9.18 (4.53, 8.58)* 7.65 (4.59, 12.77)* 10.20 (4.86, 21.42)* 2.31 (1.04, 5.14)* 13.21 (7.57, 23.05)*
CABG Reference1 Reference1 Reference1 Reference1 Reference1
Valve repair 0.87 (0.66, 1.16) 1.84 (1.16, 2.90)* 0.95 (0.72, 1.26) 0.65 (0.28, 1.50) 0.95 (0.67, 1.34)
Valve replacement 1.56 (1.31, 1.86)* 2.40 (1.81, 3.17)* 1.60 (1.34, 1.91)* 1.78 (1.24, 2.55)* 0.90 (0.72, 1.13)
CABG + Valve 4.02 (3.21, 5.03)* 4.76 (3.64, 6.22)* 3.94 (3.15, 4.94)* 3.50 (2.51, 4.87)* 2.45 (1.98, 3.02)*
Age 1.07 (1.06, 1.08)* 1.05 (1.04, 1.07)* 1.07 (1.06, 1.07)* 1.05 (1.03, 1.06)* 1.04 (1.03, 1.04)*
BMI 0.93 (0.92, 0.94)* 0.88 (0.86, 0.91)* 0.93 (0.92, 0.94)* 0.94 (0.91, 0.97)* 1.01 (0.99, 1.03)
EuroSCORE 1.37 (1.32, 1.41)* 1.23 (1.19, 1.27)* 1.38 (1.34, 1.41)* 1.12 (1.09, 1.16)* 1.25 (1.22, 1.28)*
Hb 0.50 (0.47, 0.53)* 0.90 (0.84, 0.96)* 0.56 (0.53, 0.58)* 1.00 (0.98, 1.03) 0.78 (0.74, 0.81)*
Bypass time 1.02 (1.01, 1.02)* 1.02 (1.02, 1.03)* 1.02 (1.01, 1.02)* 1.01 (1.01, 1.02)* 1.01 (1.01, 1.01)*
Aspirin use 0.83 (0.72, 0.96)* 0.58 (0.46, 0.72)* 0.80 (0.69, 0.92)* 0.98 (0.72, 1.34) 1.07 (0.90, 1.27)
Clopidogrel use 1.58 (1.31, 1.91)* 1.58 (1.18, 2.10)* 1.58 (1.30, 1.91)* 1.40 (0.97, 2.04) 1.88 (1.53, 2.31)*
The covariates with nominal data were analysed with one of their category as reference (1) and the others compared to the reference. The 
univariate analysis of the other covariates showed their influence on the outcome measures studied, independent of tranexamic acid usage. (* = p < 
0.05, statistically significant) (RBC – red blood cells, FFP – fresh frozen plasma, ICU – intensive care unit, BMI – body mass index, Hb – preoperative 
haemoglobin).
Table 4: Univariate analysis of the effects of tranexamic acid administration on outcomes of interest.
Outcome measure TA group
(n = 3359)
NTA group
(n = 832)
Odds ratio
(95% CI)
p value
RBC transfusion (n, %) 1513 (45) 420 (51) 0.80 (0.69, 0.94) 0.005
FFP Transfusion (n, %) 288 (8.6) 95 (11) 0.78 (0.57, 0.93) 0.011
Any blood product transfusion (n, %) 1543 (46) 427 (51) 0.81 (0.69, 0.94) 0.005
Return to Theatre (n, %) 160 (4.8) 69 (8.3) 0.55 (0.41, 0.74) <0.001
ICU stay > 1 day (n, %) 735 (22) 198 (24) 0.90 (0.75, 1.07) 0.234
Univariate analysis of the effects of tranexamic acid administration on outcomes of interest. The univariate analysis showed that the odds of 
receiving a transfusion or returning to theatre for bleeding were less in patients in tranexamic acid group, but that there was no difference in the 
proportion of patients staying for more than 1 day
(TA – tranexamic acid, NTA – no tranexamic acid, RBC – red blood cells, FFP – fresh frozen plasma, ICU – intensive care unit, CI – Confidence 
interval, n – number) (p < 0.05, statistically significant)BMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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tration of red blood cells, other blood products and return
to theatre for bleeding. The odds of receiving a transfusion
of red blood cells, fresh frozen plasma or any blood prod-
uct overall, or returning to theatre, were lower in patients
who received tranexamic acid (Table 7). The level of sig-
nificance was higher than in the univariate analysis. The
administration of tranexamic acid did not affect the
length of stay in ICU in this analysis.
Our subgroup analysis of patients transfused with red
blood cells showed no difference in the number of units
of red blood cells, fresh frozen plasma or all blood prod-
ucts transfused between the two groups (Table 8). There
was no difference in the proportion of patients receiving a
transfusion or staying more than 1 day in ICU between
the groups, on excluding the patients who returned to the-
atre for re-exploration (Table 9).
The analysis of blood loss showed that the median (IQR)
total blood loss was 575 mL (375, 875) in the NTA group
compared to 450 mL (325, 675) in the TA group, a highly
significant difference (p < 0.0001 Mann-Whitney test).
Corresponding figures for 12 hours blood loss are 450 mL
(300, 675) in the NTA group compared to 350 mL (250,
500) in the TA group (p < 0.001). Total blood loss for
patients returned to theatre was 1959 mL (1444, 2925) for
those patients receiving tranexamic acid compared with
2000 mL (1550, 2675) for those not receiving tranexamic
acid (a non significant difference). In contrast, a highly
significant difference (p < 0.001) in total blood loss was
observed in those patients not returned to theatre when
comparing the ones who had received tranexamic acid
(TA group: 425 mL (325, 625)) compared with the ones
who did not (non TA group: 550 mL (375, 775).
An univariate analysis of these data showed that a reduc-
tion in blood loss of 21% was expected in the TA com-
pared to the NTA group. This analysis also indicates with
high statistical significance (all p < 0.001) that postopera-
tive blood loss is greater in males, those undergoing non-
elective surgery, those undergoing CABG or CABG and
valve surgery (compared to just valve surgery), those
receiving aspirin or clopidogrel, older patients, patients
with a high BMI, high Euroscore or long bypass time. The
subsequent multivariate modelling indicated that a reduc-
tion in blood loss of 24% is expected in the TA compared
to the NTA group.
Discussion
In our hospital, the administration of tranexamic acid is
an independent factor impacting on the exposure to red
blood cells, fresh frozen plasma or any blood product. It
is also an independent factor impacting on the return to
theatre for re-exploration. These findings, obtained from
the prospective observation of a very large number of
patients in our routine clinical practice, support the trans-
lation of the evidence gathered through randomised clin-
ical trials [1-3]. The administration of tranexamic acid
indeed significantly reduced the amount of blood loss.
Interestingly, this difference was identified for the whole
population and the patients who did not return for re-
Table 7: Multivariate analysis of the effect of administration of 
Tranexamic acid on the outcomes of interest.
Risk Odds Ratio (95% CI) p value
RBC transfusion 0.58 (0.47 – 0.71) < 0.001
FFP transfusion 0.57 (0.43 – 0.75) < 0.001
Any blood product transfusion 0.58 (0.48 – 0.71) <0.001
Return to theatre 0.44 (0.32 – 0.60) <0.001
ICU stay 0.83 (0.67 – 1.04) 0.100
Multivariate analysis of the effect of administration of Tranexamic acid 
on the outcomes of interest. The multivariate analysis showed that the 
odds of receiving a transfusion of any type of product, or returning to 
theatre for bleeding, were less in patients in tranexamic acid group. 
(RBC – red blood cells, FFP – fresh frozen plasma, ICU – intensive 
care unit, CI – confidence interval) (* = p value < 0.05, statistically 
significant)
Table 6: Effect of Surgeon and Anaesthetist on outcomes of interest.
Surgeon Anaesthetist
Variable Range (as %) Overall p value Range (as %) Overall p value
TA administration -- -- 56 – 90 <0.001
RBC transfusion 41 – 51 0.007 41 – 52 0.028
FFP transfusion 5 – 15 <0.001 7 – 11 0.573
Any blood products transfusion 41 – 53 0.002 42 – 53 0.019
Return to theatre 3.6 – 8.1 0.011 3.5 – 7.6 0.146
ICU stay (> one day) 17 – 33 <0.001 17 – 27 0.005
Effect of Surgeon and Anaesthetist on outcomes of interest. The surgeon had an influence on the rate of transfusion of red blood cells, fresh frozen 
plasma and all blood products, the rate of return to theatre for bleeding and the rate of intensive care stay longer than one day. The anaesthetist 
had an influence on the rate of tranexamic acid administration, the rate of transfusion of red blood cells and all blood products and the rate of 
intensive care stay longer than one day. (TA – Tranexamic acid, RBC – red blood cells, FFP – fresh frozen plasma, ICU – intensive care unit, Range 
– proportion of patients among various surgeons and anaesthetists) (* = p value < 0.05, statistically significant)BMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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exploration, but not significant for those patients who
were taken back to theatre.
Two meta-analyses on the different pharmacological strat-
egies used to decrease excessive blood loss in cardiac sur-
gery have shown that lysine analogues decrease
postoperative transfusion. The first showed that tran-
examic acid compared to placebo reduced the proportion
of patients receiving allogeneic blood transfusions (OR
0.50, 95% CI: 0.34–0.76, 12 trials, 882 patients) but with-
out any significant effect on re-exploration for bleeding
(OR 0.91, 95% CI: 0.37 – 2.23) [2]. The authors reported
that the dosing of tranexamic acid and the blood transfu-
sion guidelines were not uniform and the sample sizes of
most of the studies included in the meta-analysis were
small. They recommended conducting large randomised
controlled trials with well defined transfusion guidelines
to establish the best use of drugs used to minimise blood
loss. In the second meta-analysis, Levi and colleagues
showed that lysine analogues (tranexamic acid and epsi-
lon aminocaproic acid) decreased perioperative blood
loss, need for transfusion, need for re-exploration and
mortality [3]. The likelihood of receiving a transfusion
was found to be lower for patients treated with lysine ana-
logues compared to those treated with placebo (OR 0.46,
95 % CI: 0.34–0.64, 14 studies, 801 patients). The need
for re-thoracotomy for any reason within 72 hours of the
operation was also decreased in patients treated with
lysine analogues (OR 0.44, 95% CI: 0.22–0.99, 11 studies,
1026 patients). Similar trends were observed when only
trials with complicated cardiac surgery were analysed.
However, these studies did not report the effects of these
drugs in uncomplicated cardiac surgery alone and did not
differentiate the effects of tranexamic acid and epsilon
aminocaproic acid separately.
This evidence was supported in a systematic review on use
of antifibrinolytics in minimising the perioperative blood
transfusion after any major surgery [1]. The authors
reported that tranexamic acid reduced the rate of red
blood cell transfusion by 34% (RR 0.66, 95% CI: 0.54 –
0.81, 18 trials, 1342 patients). In those receiving transfu-
sion, tranexamic acid resulted in a saving of 1.03 units of
RBC (95% CI: 0.67 to 1.39). However, the authors high-
lighted the significant heterogeneity among the trials,
some evidence of publication bias and the paucity of col-
lected data.
The common problems highlighted by these various
reviewers are the heterogeneity of the study population,
heterogeneity of the methods used in the trials (dosing
regimen, monitoring of bleeding and coagulation and
transfusion trigger) and the small number of patients
studied. Though all these reviews showed that tranexamic
acid reduced the proportion of patients needing a transfu-
sion, they did not exclusively study the effects of routine
use of tranexamic acid for all primary cardiac operations.
Further, the results from such meta-analyses must be
Table 9: Sub group analysis, excluding patients returned to theatre for re-exploration of bleeding.
Number of patients (%)
Outcome measure TA group (n = 3199) NTA group (n = 763) p value
RBC transfusion 1354 (42) 351 (46) 0.065
FFP Transfusion 187 (5.9) 52 (6.8) 0.312
Any blood product transfusion 1384 (43) 358 (47) 0.067
ICU stay > 1 day 627 (20) 161 (21) 0.351
Sub group analysis, excluding patients returned to theatre for re-exploration of bleeding. After excluding patients who returned to theatre for 
bleeding, there was no difference between the TA and NTA groups for the proportion of patients who received a transfusion or stayed in the 
intensive care unit for more than a day. (n = 3962, p value – not significant, Mann-Whitney U test) (TA – tranexamic acid, NTA – no tranexamic 
acid, RBC – red blood cells, FFP – fresh frozen plasma, ICU – intensive care unit)
Table 8: Subgroup analysis of patients who received a transfusion of red blood cells.
Number of units (median, IQR)
Type of transfusion TA group (n = 1543) NTA Group (n = 427) p value
RBC 2 (1,4) 3 (1,5) 0.228
FFP 0 (0,0) 0 (0,0) 0.117
Total blood products 3 (2,6) 3 (2,6) 0.289
Subgroup analysis of patients who received a transfusion of red blood cells. In patients (n = 1970) who received a transfusion, the administration of 
tranexamic acid did not affect the number of units transfused. (p value – not significant, Mann-Whitney U test)
(TA – tranexamic acid, NTA – no tranexamic acid, RBC – red blood cells, FFP – fresh frozen plasma, IQR – inter quartile range)BMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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interpreted with caution as it has been shown in the past
that larger, randomised, double blinded studies following
meta-analysis have produced contradictory results
[21,22]. For the same reasons, the authors of these reviews
recommended conducting large randomised, double
blinded, placebo controlled studies. However, no large
trial with adequate power to identify the effects of the
tranexamic acid administration compared to placebo on
transfusion is available.
A few trials, with relatively large numbers of patients,
comparing the effects of tranexamic acid with either pla-
cebo or other antifibrinolytic agents have indeed been
conducted since. In one study, Armellin et al compared
the effects of high dose of tranexamic acid with placebo in
300 patients undergoing aortic valve replacement [9].
They showed reduction in postoperative bleeding, usage
of red blood cells and fresh frozen plasma and the propor-
tion of patients receiving blood products. In another
study of primary elective cardiac operations, Casati et al
compared the effects of tranexamic acid and high dose
aprotinin in 1040 patients [10] and found that tranexamic
acid and aprotinin had similar effects on postoperative
bleeding and allogeneic transfusion. They recommended
tranexamic acid as a cheaper alternative in primary cardiac
operations. Similarly, Casati et al studied the effects of
aprotinin, tranexamic acid and epsilon aminocaproic acid
in 210 elective cardiac surgical patients and showed that
the combined costs of the pharmacological and transfu-
sion treatment were significantly lower in the tranexamic
acid group [11]. Diprose et al compared the effects of tran-
examic acid with aprotinin and placebo in 180 patients
who underwent any cardiac operation [12] and showed
aprotinin reduced bleeding and transfusion significantly,
when compared to tranexamic acid or placebo. However,
the combined drug and transfusion costs were the least in
the tranexamic acid group. Hekmat et al compared the
effects of aprotinin and tranexamic acid in 120 patients
and showed that tranexamic acid can be a cost-effective
alternative in primary CABG patients [13]. Nuttall et al
compared the effects of tranexamic acid with or with out
intraoperative autologous blood collection (combined
therapy), aprotinin and placebo in 160 patients [14]. They
showed tranexamic acid, in combination with autologous
blood collection, provided a similar reduction in bleeding
and transfusion when compared to aprotinin and was less
expensive. All these studies have repeatedly shown that
tranexamic acid provides a cheap means for reducing
transfusions in routine cardiac operations.
Intriguingly, those studies have all varied in the selected
dose of the tranexamic acid to be administered and none
established which dose is the most efficacious. Some dos-
ages have been studied, such as 10 mg.kg-1 followed by an
infusion of 1 mg.kg-1.h-1 [23-25], or 20 mg.kg-1 and 100
mg.kg-1 as an intravenous bolus [26,27]. These recom-
mendations are based on small studies and further, larger,
studies to determine the effective dose of tranexamic acid
are lacking.
It appears however that a randomised control trial to con-
vince those that remain sceptical of the effect of tran-
examic acid is not ethical. Using the available information
instead of a randomised, controlled trial to identify a clin-
ical effect or to solve a clinical problem has been described
in the literature and may be a more frequent occurrence
with the development of the automatic collection of a vast
quantity of data at the bedside [28]. This method can be
useful if the data collected are reliable and appropriate sta-
tistical tests are used for analysis [29-31]. Moreover, a
multitude of risk factors are associated with postoperative
bleeding following cardiac surgery [32] and how (or if)
they have been controlled for in the randomised control
trials is unclear, and groups may ultimately not be
matched. A randomised controlled trial accounting for
those, and mimicking clinical reality, would be very
expensive and would divert a large number of patients
from other trials, designed to answer other important clin-
ical questions. In this study, we have used the data col-
lected prospectively to identify the effects of tranexamic
acid administration in our routine patient population.
Multivariate logistic regression was used to minimise the
bias by adjusting for other confounding factors. This study
unifies, in a large group of patients, the evidence from ran-
domised controlled trials showing that tranexamic acid
administration is an independent factor impacting on the
exposure to allogeneic red blood cells, fresh frozen
plasma or any blood product and on the return to theatre
for re-exploration in patients who underwent a primary
cardiac operation.
Interestingly, tranexamic acid administration did not
impact on the length of intensive care unit (ICU) stay
though it significantly decreased the incidence of re-explo-
ration. This is different to findings from randomised stud-
ies but can be easily explained by the fact that most
patients only stayed in ICU for one night and data were
regarded as binary (stays 1 night or more). Discharge cri-
teria, in real life, are dependent on time of day when the
patient was operated, intensive care bed requirements and
the availability of ward beds.
Though the proportion of patients receiving a transfusion
was lower in the tranexamic acid group, our subgroup
analysis showed that among the transfused patients, there
was no difference in the number of units transfused
between the groups. As the data is highly positively
skewed, further analysis and interpretation of these results
is difficult. On exclusion of patients who returned to the-
atre for re-exploration, the proportion of patients whoBMC Anesthesiology 2006, 6:9 http://www.biomedcentral.com/1471-2253/6/9
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received a transfusion or who stayed in ICU for more than
one night were less in tranexamic acid, without reaching
statistical significance. The proportion of patients who
returned to theatre was lower in the tranexamic acid
group, as previously described. As these patients were at a
high risk of receiving a transfusion, exclusion of these
patients possibly removed the effect of tranexamic acid
administration on the outcome measures, though the pro-
portion of patients who returned to theatre was much less
compared to the proportion of patients who received a
transfusion. A legitimate criticism of this paper could be
that patients returned to theatre for an obvious surgical
reason should have been excluded from the analysis. We
elected not to do so as to record accurately and without
bias the cause of return is difficult and likely to be inaccu-
rate due to the inherent bias of the operator in the absence
of a neutral adjudicator. It may also be that patients with
more intra-operative blood loss are more likely to return
later as the surgeon will have had greater difficulties in
ensuring correct haemostasis.
While this observational study lacks characteristics inher-
ent to a well conducted randomised, double blinded, pla-
cebo controlled trial, it adds to the wealth of knowledge
already available by studying the effect of a therapy in a
large group of patients subjected to a normal clinical path-
way. We used multivariate logistic regression in order to
minimise a selection bias on treatment allocation. Our
large sample size means that the statistical tests have good
power. However, for the same reason, these tests can
detect very small differences as statistically significant,
such as showing that patients receiving tranexamic acid
were older, had a higher EuroSCORE and had longer
bypass times, but these differences were not clinically sig-
nificant. Other statistically significant differences were
observed in relation to postoperative blood loss, but some
of the highly significant differences were small due to the
large sample size (i.e. the median blood loss for patients
receiving clopidogrel was 500 mL compared with 450 mL
for those patients not receiving clopidogrel). In the
absence of randomisation, a subjective effect cannot
entirely be discarded by which physicians may be uncon-
sciously biased towards administering less transfusion to
those patients having received tranexamic acid. However,
we believe that this is unlikely to have tainted our primary
end-points as (1) adherence to the institutional protocol
was similar for both patients receiving or not tranexamic
acid (In the TA group 1207 (78%) of transfused patients
were transfused according to guidelines compared with
319 (75%) in the NTA group, the difference is non-signif-
icant (p = 0.124, Chi-squared test)); (2) a significant dif-
ference in the amount of blood loss measured in those
patients treated with tranexamic acid when compared
with those who were not; (3) the fact that the size of the
institution and clinical pathways usually prevent clini-
cians prescribing postoperative transfusion and involved
in the decision to take back to be aware if the administra-
tion of tranexamic acid effectively took place (as all
patients should have received it).
We did not investigate the mortality and morbidity fol-
lowing the use of tranexamic acid, neither graft patency
nor the incidence of deep vein thrombosis or pulmonary
embolism as data are not available in that regard.
This study does not suggest that tranexamic acid is a safer
alternative to other antifibribolytic, neither does it address
the possibility that it may affect morbidity as recently
reported with aprotinin [15,16,18-20].
Conclusion
In conclusion, based on the analysis of data obtained for
4191 patients operated in our institution, a standard dose
regimen of tranexamic acid reduces the need for transfu-
sion of any blood product in patients undergoing primary
cardiac surgery.
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